Moderna, Regeneron post solid earnings, eye a strong finish to 2023

Moderna and Regeneron released solid earnings reports Thursday morning and anticipate a strong finish to 2023.

Due to a sharp drop in sales, Moderna’s quarterly revenues totaled $344 million, down from $4.7 billion this time last year, and the company posted a net loss of $1.4 billion as well as a loss per share of $3.62.